Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Total Debt (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Total Debt for 2 consecutive years, with $99.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Debt changed N/A to $99.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $99.9 million, a N/A change, with the full-year FY2023 number at $207.0 million, changed N/A from a year prior.
  • Total Debt was $99.9 million for Q3 2025 at Inhibrx Biosciences, up from $99.3 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $207.0 million in Q4 2023 to a low of $98.7 million in Q1 2025.